Novogen Limited (ASX: NRT) has announced that a patent application covering its drugs Cantrixil and Trilexium has been accepted in Australia.
If the drug is approved, the company says Cantrixil will be used for early stage cancers in the abdominal cavity.
Trilexium will be used for patients suffering from a rare brain tumour known as DIPG.
The patent provides protection around method of manufacture, composition of matter and method of use out til 2032.
Novogen reported a loss of $7.3 million at 30 June 2015.
